Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
暂无分享,去创建一个
M. Pfeffer | S. Yusuf | J. McMurray | K. Swedberg | C. Granger | S. Stewart | R. Dietz | D. V. van Veldhuisen | J. Ostergren | J. Vanhaecke | F. Andersson | K. Svensson | A. C. Solal | S. Stewart